A Phase 1 interventional study of CDC infusion in Dilated Cardiomyopathy, sponsored by Okayama University. Completed at 1 site in Japan. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2021-11-26.
Sponsored by Okayama University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A phase 1 prospective study to determine the procedural feasibility and safety and preliminary efficacy of intracoronary infusion of cardiosphere-derived cells (CDCs) in patients with dilated cardiomyopathy.
Five consecutive patients will be enrolled to a phase 1 study to verify the procedural feasibility and safety with the CDC infusion group.
256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.
This study's enrollment of 5 is below the median of 43 across 145 interventional studies indexed under Cardiomyopathy, Dilated.
Browse Cardiomyopathy, Dilated studies →Okayama University is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CDCs infusion by coronary intervention.
Biological: CDC infusion
Injection of CDCs (0.3 million per kg of body weight).
Number of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs.
Assessment of major adverse cardiac events include death, sustained/symptomatic ventricular tachycardia, aggravation of heart failure, acute coronary syndrome, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.
Time frame: 6 months after CDC treatment
Change in Ejection Fraction
To determine the changes in cardiac function by ejection fraction with cardiac MRI evaluation in CDC-treated participants from baseline to 6 months of follow up.
Time frame: 6 months after protocol treatment
| Milestone | CDC Infusion |
|---|---|
| Started | 5 |
| Completed | 5 |
| Not completed | 0 |
Assessment of major adverse cardiac events include death, sustained/symptomatic ventricular tachycardia, aggravation of heart failure, acute coronary syndrome, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.
| Participants | CDC Infusion |
|---|---|
| Number of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs. | 1 |
To determine the changes in cardiac function by ejection fraction with cardiac MRI evaluation in CDC-treated participants from baseline to 6 months of follow up.
| percentage of ejection fraction | CDC Infusion |
|---|---|
| Change in Ejection Fraction | 4.5 ± 10.2 |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CDC Infusion | 1/5 (20%) | 1/5 (20%) | 0/5 (0%) |
| Event | CDC Infusion |
|---|---|
| heart failureCardiac disorders | 1/5 |
| infectionRespiratory, thoracic and mediastinal disorders | 1/5 |
| ischemic eventCardiac disorders | 1/5 |
Consecutive enrollment of 5 patients to receive CDC infusion
| Age, Continuous(years) | CDC Infusion |
|---|---|
| Mean | 11.4 ± 6.7 |
| Sex: Female, Male(Participants) | CDC Infusion |
|---|---|
| Female | 3 |
| Male | 2 |
| Race (NIH/OMB)(Participants) | CDC Infusion |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 5 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Cardiac Function(percentage of baseline ejection fraction) | CDC Infusion |
|---|---|
| Mean | 28.5 ± 10.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2017 to primary completion in Sep 2018, 17 months.
Results were first posted in Nov 2021, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Okayama University